Rising tensions between Canada and China are threatening to derail what was once touted as a promising partnership to develop a covid-19 vaccine.
The Race...CanSino Biologics, a Chinese company, led the vaccine race by starting trials on humans in March. CanSino's early success was in part due to a partnership with the National Research Council of Canada which allowed for tests to be conducted in Canada as well as Canadian technology contributed to the vaccine's development. Over the last few months the Chinese-Canadian candidate has yet to start final stage trials, falling behind competitors.
The Delay...Vials of the vaccine were slated to be shipped to Canada by now in order for Phase III trials to begin in the fall, but the shipments were never approved for export by Chinese customs authorities.
The Tension.. The delayed shipment is not a bureaucratic error but a result of a rocky relationship between Canada and China, sparked by our arrest and detainment of Huawei's CFO Meng Wanzhou at the request of the US, and China's subsequent retaliatory measures.
The Fallout...CanSino's stock (OTC:CASBF), which has risen 150% over the course of the year, fell 40% on this news. Now that Canada may be off the table as a trial site, the company announced Russia as a new site, which led to another 11% loss.
Big Picture...This dust up may be a set back for what started off as the most promising vaccine, but there are plenty of other candidates moving at warp speed, experts still see chance for an approval this fall.
The Race...CanSino Biologics, a Chinese company, led the vaccine race by starting trials on humans in March. CanSino's early success was in part due to a partnership with the National Research Council of Canada which allowed for tests to be conducted in Canada as well as Canadian technology contributed to the vaccine's development. Over the last few months the Chinese-Canadian candidate has yet to start final stage trials, falling behind competitors.
The Delay...Vials of the vaccine were slated to be shipped to Canada by now in order for Phase III trials to begin in the fall, but the shipments were never approved for export by Chinese customs authorities.
The Tension.. The delayed shipment is not a bureaucratic error but a result of a rocky relationship between Canada and China, sparked by our arrest and detainment of Huawei's CFO Meng Wanzhou at the request of the US, and China's subsequent retaliatory measures.
The Fallout...CanSino's stock (OTC:CASBF), which has risen 150% over the course of the year, fell 40% on this news. Now that Canada may be off the table as a trial site, the company announced Russia as a new site, which led to another 11% loss.
Big Picture...This dust up may be a set back for what started off as the most promising vaccine, but there are plenty of other candidates moving at warp speed, experts still see chance for an approval this fall.